The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Raluy Callado, Mireia ^a   Chen, Wen Hung ^b   Whiteman, David A H ^c   Fang, Juanzhi ^c   Wiklund, Ingela ^a  

^a EVIDERA   (United Kingdom)

^b EVIDERA   (United States)

^c Shire HGT   (United States)

Author keywords

Health related quality of life; Hunter syndrome; Lysosomal storage disease; Mucopolysaccharidosis type II; Patient reported outcomes

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; ENZYME REPLACEMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUNTER SYNDROME; HUNTER SYNDROME FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARENT; QUALITY OF LIFE; RARE DISEASE; SCHOOL CHILD; SELF ESTEEM; SELF REPORT; CLINICAL TRIAL; FEMALE; LYSOSOME STORAGE DISEASE; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE;

FEMALE; HUMANS; LYSOSOMAL STORAGE DISEASES; MALE; MUCOPOLYSACCHARIDOSIS II; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84880029146     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-101     Document Type: Article

References (34)

1. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Marti-Herrero M, Munguira-Aguado P, Galan-Gomez E, Eur J Med Genet 2010 53 371 377 10.1016/j.ejmg.2010.07.013 20709629
2. Incidence of the mucopolysaccharidoses in Northern Ireland. Nelson J, Hum Genet 1997 101 355 358 10.1007/s004390050641 9439667
3. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Young ID, Harper PS, Arch Dis Child 1982 57 828 836 10.1136/adc.57.11.828 6816147
4. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Young ID, Harper PS, Dev Med Child Neurol 1983 25 481 489 6413286
5. Hearing Impairment in 2008: a compilation of available epidemiological studies. Pascolini D, Smith A, Int J Audiol 2009 48 473 485 10.1080/ 14992020902803120 19444763
6. WHO ear and hearing disorders survey protocol for a population-based survey of prevalence and causes of deafness and hearing impairment and other ear disorders [ http://whqlibdoc.who.int/hq/1999/WHO-PBD-PDH-99.8(1).pdf ]
7. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M, et al. Genet Med 2011 13 95 101 10.1097/GIM.0b013e3181fea459 21150784
8. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A, Mol Genet Metab 2007 90 329 337 10.1016/j.ymgme.2006.09.001 17185020
9. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, et al. Genet Med 2006 8 465 473 10.1097/01.gim.0000232477. 37660.fb 16912578
10. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). da Silva EM, Strufaldi MW, Andriolo RB, Silva LA, Cochrane Database Syst Rev 2011 11 D008185 22071845
11. Adaptive functioning and health-related quality of life of patients with mucopolysaccharidosis type ii (hunter syndrome). Needham MC, Packman W, Packman W, Packman S, Mol Genet Metab 2012 105 344
12. Quality of life after treatment for mucopolysaccharidoses. Kunin-Batson A, Erickson N, Ahmed A, Yund B, Sharipo E, Mol Genet Metab 2012 105 42
13. A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Weekly and Every Other Week Dosing Regimens of Iduronate-2-Sulfatase Enzyme Replacement Therapy in Patients With MPS II. Shire Human Genetic Therapies, Inc, ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US) 2000 [cited 2013 Jan 15]. Available from: http://clinicaltrials.gov/show/NCT00069641 NLM Identifier: NCT00069641
14. The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) questionnaire: evaluation of measurement properties. Wiklund I, Raluy-Callado M, Stull DE, Jangelind Y, Whiteman DA, Chen WH, Qual Life Res 2013 22 874 884
15. Preliminary definition of improvement in juvenile arthritis. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A, Arthritis Rheum 1997 40 1202 1209 9214419
16. Landgraf JM, Abetz LN, Ware JE, The CHQ User's Manual Boston: The Health Institute, New England Medical Center 1999
17. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Valayannopoulos V, de Blic J, Mahlaoui N, Stos B, Jaubert F, Bonnet D, Fischer A, de Lonlay P, Pediatrics 2010 126 1242 e1247 10.1542/peds.2009-2843 20974778
18. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Horsman J, Furlong W, Feeny D, Torrance G, Health Qual Life Outcomes 2003 1 54 10.1186/1477-7525-1-54 14613568
19. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, Cate RT, Koopman-Keemink Y, van Santen-Hoeufft M, Raat H, van Suijlekom-Smit LW, Ann Rheum Dis 2010 69 138 142 10.1136/ard.2009.111260 19581280
20. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. Pediatric Outcomes Instrument Development Group. Pediatric Orthopaedic Society of North America. Daltroy LH, Liang MH, Fossel AH, Goldberg MJ, J Pediatr Orthop 1998 18 561 571 9746401
21. Lysosomal storage diseases: natural history and ethical and economic aspects. Beutler E, Mol Genet Metab 2006 88 208 215 10.1016/j.ymgme.2006.01.010 16515872
22. The functional independence measure: a new tool for rehabilitation. Keith RA, Granger CV, Hamilton BB, Sherwin FS, Adv Clin Rehabil 1987 1 6 18 3503663
23. Hearing loss in Hunter's syndrome-mucopolysaccharidosis II. Peck JE, Ear Hear 1984 5 243 246 6432613
24. Use of the child health questionnaire in a sample of moderate and low-income inner-city children with asthma. Asmussen L, Olson LM, Grant EN, Landgraf JM, Fagan J, Weiss KB, Am J Respir Crit Care Med 2000 162 1215 1221 10.1164/ajrccm.162.4.2001067 11029320
25. Hearing Loss in Patients With Mucopolysaccharidosis II: Data From HOS-the Hunter Outcome Survey. Keilmann A, Nakarat T, Bruce IA, Molter D, Malm G, on behalf of the HOS Investigators, J Inherit Metab Dis 2012 35 343 353 10.1007/s10545-011-9378-5 21866356
26. Low self-esteem during adolescence predicts poor health, criminal behavior, and limited economic prospects during adulthood. Trzesniewski KH, Donnellan MB, Moffitt TE, Robins RW, Poulton R, Caspi A, Dev Psychol 2006 42 381 390 16569175
27. Assessing the quality of life of children. Bullinger M, Mackensen SV, Langraf J, Qual Life Res 1994 3 41
28. Children and adult perceptions of childhood asthma. Guyatt GH, Juniper EF, Griffith LE, Feeny DH, Ferrie PJ, Pediatrics 1997 99 165 168 10.1542/peds.99.2.165 9024440
29. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs). Brunner HI, Maker D, Grundland B, Young NL, Blanchette V, Stain AM, Feldman BM, Med Decis Making 2003 23 314 322 10.1177/0272989X03256008 12926581
30. Prepubertal children with short stature have a different perception of their well-being and stature than their parents. Erling A, Wiklund I, Albertsson-Wikland K, Qual Life Res 1994 3 425 429 10.1007/BF00435394 7866360
31. Health-related quality of life: changes in children undergoing chemotherapy. Banks BA, Barrowman NJ, Klaassen R, J Pediatr Hematol Oncol 2008 30 292 297 10.1097/MPH.0b013e3181647bda 18391698
32. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Nishimura K, Izumi T, Tsukino M, Oga T, Chest 2002 121 1434 1440 10.1378/chest.121.5.1434 12006425
33. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Jones PW, Agusti AG, Eur Respir J 2006 27 822 832 10.1183/09031936.06. 00145104 16585091
34. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meirleir L, Guffon N, Guillen-Navarro E, Hensman P, Jones S, et al. Orphanet J Rare Dis 2011 6 72 10.1186/1750-1172-6-72 22059643